Dr. Rui Chang, founder of Path Biotech and professor at the University of Arizona, is leveraging artificial intelligence to revolutionize Alzheimer's and dementia research. With over 16 years of experience in AI, Dr. Chang's work includes analyzing entire genomes simultaneously, predicting drug targets, and launching AI-predicted clinical trials for Alzheimer's treatment. His research extends to Lewy Body Dementia and glioblastoma, collaborating with institutions like Mayo Clinic. Dr. Chang has also developed a nutraceutical product, Cognition Protect, for those concerned about cognitive decline. His work represents a significant advancement in precision medicine and offers hope for more effective treatments in neurology. The interview highlights the potential of AI in accelerating medical research and improving patient outcomes. #AlzheimersResearch #ArtificialIntelligence #BrainHealth #Neuroscience #PrecisionMedicine #AIinHealthcare #DementiaResearch #CognitiveHealth